Previous close | 0.3275 |
Open | 0.3300 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.3020 - 0.3300 |
52-week range | 0.2300 - 2.5400 |
Volume | |
Avg. volume | 2,381,780 |
Market cap | 230.94M |
Beta (5Y monthly) | -0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2250 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
VANCOUVER, Wash., January 25, 2022--Today the Board of Directors ("the Board") of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a leadership transition plan. Effective immediately, Antonio Migliarese, currently CytoDyn’s Chief Financial Officer, has been appointed interim President. The Board of Directors terminated the employment of Nader Z. Pourhassan,
VANCOUVER, Wash., January 13, 2022--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.
VANCOUVER, Wash., January 10, 2022--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that a research paper entitled "Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects" has been accepted, peer reviewed and is available as a journal pre-proof on ScienceDirect. ScienceDirect provides